Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

ObjectiveWe conducted a retrospective cohort study to examine cancer risk in a large cohort of systemic lupus erythematosus (SLE) patients in California.MethodsThe cohort consisted of individuals with SLE derived from statewide patient discharge data during the period 1991–2002. SLE patients were followed using cancer registry data to examine patterns of cancer development. Standardized incidence ratios (SIRs) and 95% CI were calculated to compare the observed to expected numbers of cancers based on age-, race-, and sex-specific incidence rates in the California population.ResultsThe 30,478 SLE patients were observed for 157,969 person-years. A total of 1,273 cancers occurred within the observation interval. Overall cancer risk was significantly elevated (SIR = 1.14, 95% CI = 1.07–1.20). SLE patients had higher risks of vagina/vulva (SIR = 3.27, 95% CI = 2.41–4.31) and liver cancers (SIR = 2.70, 95% CI = 1.54–4.24). Elevated risks of lung, kidney, and thyroid cancers and several hematopoietic malignancies were also observed. Individuals had significantly lower risks of several screenable cancers, including breast, cervix, and prostate.ConclusionsThese data suggest that risks of several cancer types are elevated among SLE patients. Detailed studies of endogenous and exogenous factors that drive these associations are needed.

[1]  D. Isenberg,et al.  Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. , 2000, Rheumatology.

[2]  J. Janosky,et al.  Risk of malignancy in women with systemic lupus erythematosus. , 1995, The Journal of rheumatology.

[3]  G. Miller,et al.  Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. , 1990, The Journal of urology.

[4]  H. Desmurs,et al.  Existe-t-il un risque particulier lié aux infections à papillomavirus chez les femmes lupiques ? , 1999 .

[5]  S. Bernatsky,et al.  Malignancy and systemic lupus erythematosus , 2002, Current rheumatology reports.

[6]  D. Gladman,et al.  How to improve morbidity and mortality in systemic lupus erythematosus. , 2000, Rheumatology.

[7]  B. Armstrong,et al.  Cancer in connective tissue disease. , 1982, Arthritis and rheumatism.

[8]  M. Petri,et al.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.

[9]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. , 1997, The Journal of rheumatology.

[10]  E. Pukkala,et al.  Increased risk of cancer in patients with systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.

[11]  H. Howe,et al.  Increased risk of malignancy in patients with systemic lupus erythematosus. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[12]  R Finnegan,et al.  ICD-9-CM , 1986, Journal.

[13]  W E Hammond,et al.  Health Level 7: an application standard for electronic medical data exchange. , 1991, Topics in health record management.

[14]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[15]  D. Gladman,et al.  Malignancy in systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[16]  E. Zintzaras,et al.  The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.

[17]  A. Dawson,et al.  SYSTEMIC LUPUS ERYTHEMATOSUS AND LYMPHOMA , 1978, The Lancet.

[18]  D. Gladman,et al.  Mortality studies in SLE: how far can we improve survival of patients with SLE. , 2004, Autoimmunity reviews.

[19]  I. Bruce,et al.  Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. , 1998, Clinical and experimental rheumatology.

[20]  M. Liang,et al.  Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. , 1997, Arthritis and rheumatism.

[21]  E. A.Ortiza,et al.  Bladder Cancer after Cyclophosphamide Therapy for Lupus Nephritis , 2008 .

[22]  S. Oertel,et al.  Immunosurveillance, Immunodeficiencies and Lymphoproliferations , 2012, Recent Results in Cancer Research.

[23]  J. Boivin,et al.  Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. , 2002, Journal of Rheumatology.

[24]  J. Dankert,et al.  DO ANAEROBES CAUSE CHRONIC PROSTATITIS? , 1981, The Lancet.

[25]  M. Lishner,et al.  Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. , 1990, Acta Haematologica.

[26]  A. Ekbom,et al.  A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.

[27]  K. Steinsson,et al.  Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus , 2003, Lupus.

[28]  A. Cohen,et al.  Malignancy in a series of 70 patients with systemic lupus erythematosus. , 1974, Arthritis and rheumatism.

[29]  W. Swedler,et al.  Systemic lupus erythematosus and Hodgkin's lymphoma. , 1993, The Journal of rheumatology.

[30]  L. Kinlen.  Malignancy in autoimmune diseases. , 1992, Journal of autoimmunity.

[31]  Y. Shoenfeld,et al.  SLE and Cancer , 2000 .

[32]  P. Lipsky,et al.  Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. , 1992, The Journal of rheumatology.

[33]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[34]  J. Sibley,et al.  Systemic lupus erythematosus and the risk of malignancy , 2001, Lupus.

[35]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[36]  C. Ridley,et al.  Lichen sclerosus et atrophicus associated with systemic lupus erythematosus. , 1985, Journal of the American Academy of Dermatology.

[37]  P. Wiernik,et al.  Systemic lupus erythematosus and B-cell hematologic neoplasm , 2001, Lupus.

[38]  R. Hoover,et al.  Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[39]  I. Bruce,et al.  Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[40]  D. Gladman,et al.  An international cohort study of cancer in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[41]  A. Ekbom,et al.  Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus , 2002, Scandinavian journal of rheumatology.

[42]  D. Isenberg,et al.  Hodgkin's lymphoma in systemic lupus erythematosus. , 2007, Rheumatology.

[43]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[44]  A. Morley,et al.  Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. , 1982, British medical journal.

[45]  J. Seiffert,et al.  The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. , 1990, Topics in health record management.

[46]  N. Rosenthal,et al.  Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. , 1996, American journal of clinical pathology.

[47]  R. Gibbons,et al.  Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. , 1988, Arthritis and rheumatism.

[48]  Deborah Melewski.  Vality Technology Inc. , 1994 .

[49]  O. Nived,et al.  Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden , 2001, Lupus.

[50]  M. Hearth-Holmes,et al.  Prevalence of Active Hepatitis C Virus Infection in Patients with Systemic Lupus Erythematosus , 2001, The American journal of the medical sciences.

[51]  B. de Wazières,et al.  [Does a particular risk associated with papillomavirus infections exist in women with lupus?]. , 1999, La Revue de medecine interne.

[52]  D. Gladman,et al.  Non-Hodgkin’s lymphoma in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[53]  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. , 2006, Annals of the rheumatic diseases.

[54]  P. Chan,et al.  Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. , 2004, Arthritis and rheumatism.

[55]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[56]  D. Gladman,et al.  Race/ethnicity and cancer occurrence in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[57]  O. Nived,et al.  Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. , 2000, The Journal of rheumatology.

[58]  C. Pineau,et al.  Cancer screening in patients with systemic lupus erythematosus. , 2006, The Journal of rheumatology.

[59]  N. Taub,et al.  Environmental factors predicting nephritis in systemic lupus erythematosus. , 1993, Annals of the rheumatic diseases.

[60]  H. Riess,et al.  Immunosurveillance, immunodeficiency and lymphoproliferations. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.